Kura Oncology, Inc. (NASDAQ:KURA – Get Rating)’s stock price traded up 3.9% during mid-day trading on Wednesday after Credit Suisse Group raised their price target on the stock from $27.00 to $29.00. Credit Suisse Group currently has an outperform rating on the stock. Kura Oncology traded as high as $18.79 and last traded at $18.64. 9,518 shares changed hands during trading, a decline of 99% from the average session volume of 796,306 shares. The stock had previously closed at $17.94.
A number of other brokerages have also recently commented on KURA. Cantor Fitzgerald started coverage on shares of Kura Oncology in a research report on Tuesday. They set an “overweight” rating and a $30.00 price target on the stock. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 18th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.14.
Hedge funds have recently modified their holdings of the company. Deep Track Capital LP purchased a new position in Kura Oncology in the 4th quarter valued at approximately $35,700,000. Deerfield Management Company L.P. Series C grew its stake in Kura Oncology by 51.8% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 3,513,756 shares of the company’s stock valued at $49,193,000 after buying an additional 1,198,339 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Kura Oncology by 222.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,680,196 shares of the company’s stock valued at $27,018,000 after buying an additional 1,158,356 shares in the last quarter. Suvretta Capital Management LLC grew its stake in Kura Oncology by 45.2% in the 4th quarter. Suvretta Capital Management LLC now owns 3,572,419 shares of the company’s stock valued at $50,014,000 after buying an additional 1,112,217 shares in the last quarter. Finally, Aaron Wealth Advisors LLC grew its stake in Kura Oncology by 1,503.0% in the 1st quarter. Aaron Wealth Advisors LLC now owns 910,690 shares of the company’s stock valued at $56,635,000 after buying an additional 853,877 shares in the last quarter. Institutional investors own 94.65% of the company’s stock.
The firm has a market capitalization of $1.26 billion, a PE ratio of -9.57 and a beta of 1.07. The business’s 50 day moving average is $14.49 and its two-hundred day moving average is $14.67.
Kura Oncology (NASDAQ:KURA – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the previous year, the business earned ($0.46) earnings per share. On average, sell-side analysts expect that Kura Oncology, Inc. will post -2.19 EPS for the current fiscal year.
About Kura Oncology (NASDAQ:KURA)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
Featured Articles
Receive News & Ratings for Kura Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kura Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.
Read More: Kura Oncology (NASDAQ:KURA) Stock Price Up 3.9% After Analyst Upgrade